Erlotinib beyond progression study: Randomized phase II study comparing chemotherapy plus erlotinib with chemotherapy alone in EGFR tyrosine kinase inhibitor (TKI)-responsive, non-small cell lung cancer (NSCLC) that subsequently progresses.

Authors

Balazs Halmos

New York-Presbyterian Hospital, Columbia University, New York, NY

Balazs Halmos , Nathan A. Pennell , Gregory Alan Otterson , Shirish M. Gadgeel , Tarek Mekhail , Michael Robert Snell , J. Phillip Kuebler , Pingfu Fu , Neelesh Sharma , Afshin Dowlati

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2011 ASCO Annual Meeting

bookmark_border

Erlotinib beyond progression study: Randomized phase II study comparing chemotherapy plus erlotinib with chemotherapy alone in EGFR TKI-responsive, advanced non-small cell lung cancer (NSCLC) that subsequently progresses.

First Author: B. Halmos

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

A phase II trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR tyrosine kinase inhibitors (TKIs) (ILLUMINATE).

First Author: Chee Khoon Lee

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

SHERLOC: A phase 2 study of MM-121 plus with docetaxel versus docetaxel alone in patients with heregulin (HRG) positive advanced non-small cell lung cancer (NSCLC).

First Author: Lecia V. Sequist

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant NSCLC.

First Author: Jamie E. Chaft